BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models-Reference-Cited by-同舟云学术

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Published:2008-04-14 Issue:34 Volume:27 Page:4702-4711
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Li D,Ambrogio L,Shimamura T,Kubo S,Takahashi M,Chirieac L R,Padera R F,Shapiro G I,Baum A,Himmelsbach F,Rettig W J,Meyerson M,Solca F,Greulich H,Wong K-K

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2008109.pdf

Reference37 articles.

1. Bedano PM, Hanna NH . (2006). Salvage therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 1: 582–587.

2. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J et al. (1985). Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132–1139.

3. Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. (2005). ErbB-3 mediates PI3K activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102: 3788–3793.

4. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039–1043.

5. Eskens FA, Mom CH, Planting AS, Gietema JA, Amelsberg A, Huisman H et al. (2008). A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98: 80–85.

Cited by 1272 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Oxidative stress-mediated protein sulfenylation in human diseases: Past, present, and future;Redox Biology;2024-10

3. Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy;Bioorganic Chemistry;2024-10

4. 1,3,5-Triazine as a promising scaffold in the development of therapeutic agents against breast cancer;European Journal of Medicinal Chemistry;2024-10

5. Recent advances in the design of small molecular drugs with acrylamides covalent warheads;Bioorganic & Medicinal Chemistry;2024-10